---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-007383"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:45:11.638744+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q4 2024 revenue $14.2M (down 3% YoY); net loss narrows to $4.6M; submits AYON 510(k) ahead of schedule

## Summary
- Q4 total revenue $14.2M (-3% YoY); Advanced Energy flat at $12.1M. Full year revenue $48.1M (-8%).
- Net loss Q4 $4.6M ($0.12 per share) vs $9.6M loss in Q4 2023; adjusted EBITDA loss $2.2M vs $4.7M.
- Full year 2024 net loss $23.5M ($0.66 per share) vs $18.7M; adjusted EBITDA loss $14.3M vs $13.4M.
- Submitted 510(k) for AYON Body Contouring System ~90 days early; planned launch back half 2025 pending clearance.
- Cost restructuring: workforce reduced ~25%, annual savings ~$4.3M. 2025 guidance: revenue $47.6-49.0M, opEx <$40M.

## SEC filing metadata
- accession: 0001437749-25-007383
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774925007383/0001437749-25-007383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774925007383/apyx20241230_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-007383
- JSON: https://secwatch.observer/filing/0001437749-25-007383.json
- Plain text: https://secwatch.observer/filing/0001437749-25-007383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.